158 million covered lives across the United States now include access to Nerivio, Theranica's FDA-cleared Remote Electrical Neuromodulation wearable device, a count the company says exceeds half the U.S. insured population. A wave of recent payer coverage expansions, per a July 9, 2026 announcement from Theranica's offices in Bridgewater, N.J. and Caesarea, Israel, drove the total to the level the company equates with leading prescription migraine drugs. Coverage parity at that scale positions a wearable device as a formulary-comparable alternative to oral pharmacotherapy.
The parity comparison
| Metric | Value | Status |
|---|---|---|
| Covered lives | 158 million | Reported |
| Share of U.S. insured population | Exceeds 50% | Reported |
| Benchmark | Leading prescription migraine drugs | Reported |
Parity with leading prescription migraine treatments means Nerivio now appears across as many covered-lives plans as the oral standard of care. Theranica is framing the count as a coverage equivalence, placing the REN wearable in the same access tier as established prescription options. Covered-lives parity is a supply-side figure. It does not guarantee identical cost-sharing across those 158 million members; prior authorization requirements and copay tiers vary by plan.
What the 158 million does and does not show
158 million is a count of insured Americans in plans that list Nerivio as a covered benefit. It is not a prescriptions-written or devices-dispensed figure. The conversion from covered to actively treating depends on per-unit pricing and reimbursement structures, neither of which Theranica disclosed in this announcement.
Nerivio operates through Remote Electrical Neuromodulation, a wearable delivery mechanism the FDA has cleared. That cleared-device classification shapes how payers categorize and reimburse it, making each coverage expansion decision a direct factor in patient access at scale.
Expansion detail not yet disclosed
Theranica attributed the milestone to a wave of recent payer coverage expansions without naming the specific payers or plan types that joined. The breakdown of the 158 million by commercial insurance, Medicare Advantage, Medicaid, or U.S. geography was absent from the July 9, 2026 announcement.